French Shipping Giant Hails US-China Deal After Freight Slumps
Rodolphe Saade, Chief Executive Officer of CMA CGM SA, the world's third-largest container carrier, hailed a truce in the trade war between Washington and Beijing.
'For CMA CGM, it's good news,' Saade said during a hearing in the French Senate on Monday. 'We've lost 50% of our volumes toward the US since the start of this crisis.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Florian Wirtz £116m transfer problem now unlikely as Liverpool trend set to continue
Liverpool are going with the Flo. After a few weeks haggling with Bayer Leverkusen, a deal for attacking midfielder Florian Wirtz has been agreed with the Reds paying £100million with a further £16m made up of achievable add-ons. Advertisement The transfer is expected to go through when the window reopens next week and will make Wirtz the most expensive player in Liverpool's history - the 21st person to assume such an accolade since the Second World War. While taking on such a mantle can weigh heavy on some shoulders, the Reds have a reasonably decent record in extracting full value from such purchases. Success, though, isn't necessarily guaranteed. READ MORE: Liverpool have no Florian Wirtz alternative as truth about transfer spend emerges READ MORE: Why Liverpool are unable to take part in Club World Cup despite initially qualifying Wirtz will oust Darwin Nunez as the club record transfer, with the Uruguayan having arrived almost three years to the day the deal for the 22-year-old Germany international was reached on Friday. Advertisement Liverpool committed to spending £85.3m on Nunez, who was largely viewed as a signing championed by then boss Jurgen Klopp rather than being aggressively pursued by the Reds' recruitment team. While by no means a failure, Nunez must be regarded as a qualified success at best. A total of 40 goals and 22 assists in 143 appearances, while playing his part in a Premier League title triumph, would be welcomed by most players. But there has always been a sense that more could have been achieved on a personal level, with the arrival of Arne Slot as head coach last summer highlighting his qualities don't necessarily match what is required from a Liverpool number nine at present. Few would be surprised if Nunez departed this summer. The same, though, cannot be said for the two record signings before the forward. Virgil van Dijk, taken from Southampton for £75m in January 2018, and Mohamed Salah, a £43.9m purchase from Roma six months earlier, remain key figures in the Liverpool squad with both strong contenders to be in the club's greatest XI of all time. Advertisement Andy Carroll, though, was another story of what might have been. His £35m signing came on the same day Luis Suarez arrived and Fernando Torres departed, and in many respects the odds were always stacked against the Newcastle United man as Suarez completely overshadowed his new team-mate. There were some flashes - scoring at Wembley in the FA Cup semi-final and final - but the arrival of Brendan Rodgers as boss brought an end to his time after barely 18 months. Forwards ruled the roost for a good 30 years. Torres had been a record buy in July 2007 when taken from Atletico Madrid, and flourished under Rafael Benitez before the ill-fated Roy Hodgson era accelerated his exit. Djibril Cisse was signed by Gerard Houllier but only arrived after Benitez was appointed, and never truly regained momentum after a horror leg break at Blackburn Rovers. Nevertheless, he did score a penalty in the Champions League final win over AC Milan, two goals in the UEFA Super Cup win over CSKA Moscow and netted in the FA Cup final against West Ham United. Emile Heskey was a key part of Houllier's treble-winning team of 2001, and while both Stan Collymore and Dean Saunders regularly found the target in the 1990s - the latter winning the FA Cup - that neither made it to a third season spoke volumes. Peter Beardsley, though, won two titles and an FA Cup as part of the attack-minded Liverpool side of the late 1980s. Advertisement Before Beardsley came a string of other successes, with Mark Lawrenson in 1981 and, throughout the 1970s, John Toshack, Ray Kennedy, David Johnson and, of course, Kenny Dalglish. All won multiple honours both home and abroad for Liverpool. And if the late 1960s saw two players in Tony Hateley and Alun Evans who, for differing reasons, weren't quite able to live up to expectations, the earlier purchases of Emlyn Hughes and Ian St John most certainly did, along with the club's first post-war record signing, Albert Stubbins. Wirtz, then, is following in the footsteps of some genuine Liverpool royalty both past and present. And history suggests he is more likely than not to leave a successful legacy. Anfield awaits.
Yahoo
20 minutes ago
- Yahoo
Joshua Kimmich becomes first Bayern Munich player to break silence on Florian Wirtz to Liverpool
Joshua Kimmich has admitted that Bayern Munich are in desperate need of attacking reinforcements as the German giants reel from missing out on Florian Wirtz to Liverpool. On Friday, the Reds struck an agreement that could be worth a British record £116million for Bayer Leverkusen attacker Wirtz. Advertisement Bundesliga champions Bayern had initially been considered front-runners to sign Wirtz, only for Arne Slot and Liverpool to convince the 22-year-old to move to Merseyside. Wirtz informed the Reds of his decision in May, paving the way for Liverpool sporting director Richard Hughes to thrash out an agreement with Leverkusen counterpart Simon Rolfes, with Bayern - who had been confident of striking a deal themselves - disappointed. READ MORE: Liverpool braced for Andy Robertson transfer bid as Atletico Madrid consider move READ MORE: Liverpool goalkeeper set to complete Ajax transfer after signing new contract Advertisement It leaves Bayern on the lookout for recruits with club legend Thomas Muller released and winger Leroy Sane choosing not to renew his contract and instead sign for Turkish giants Galatasaray. And with Vincent Kompany's side competing in FIFA's new Club World Cup competition in the United States, Kimmich believes big name exits and Wirtz's decision leave Bayern light in attack. "You'll have to ask the club what their plans are," he said. "Of course, you have the feeling that we could do something – with Flo (Wirtz) not coming, with Leroy leaving, with Thomas leaving. 'I was surprised that he (Sane) is going to Turkey. I didn't expect that. But it's his decision and he'll have his reasons for it.' Advertisement Kompany wouldn't be drawn on transfers but sporting director Max Eberl previously made no secret of Bayern's disappointment at missing out on Wirtz and the need to spend in the transfer market. He said: "I am sure that we will have a competitive team - and that we will also have the finances under control." And on Wirtz, he added: ""If I'm honest, I don't know if we could have paid what Liverpool are apparently paying now. "Florian Wirtz is an outstanding player. We could have imagined signing him. But when a door closes, another opens. "The focus is on the squad we have here. We've brought along some young players, and now we've added two Germany internationals in Tom Bischof and Jonathan Tah, who have come in on free transfers. That's already a big step. 'We have a clear plan on how we want to implement things. But there's still a lot to do. I'm certain we will have a very strong squad."
Associated Press
38 minutes ago
- Associated Press
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congressdescribe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translational pharmacology modeling data supporting verekitug's Thymic Stromal Lymphopoietin (TSLP) receptor targeting as a mechanism for greater potency when compared to treatments targeting the TSLP ligand. Data were presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress taking place June 13-16, 2025, in Glasgow, United Kingdom. TSLP is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective treatment approach. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. Upstream is developing verekitug in multiple severe respiratory diseases including severe asthma, COPD, and CRSwNP. Verekitug is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. 'These data reinforce our belief in the differentiated profile of verekitug, as the model elucidates important biologic parameters that drive the differentiated rapid, substantial and sustained treatment effects observed through TSLP receptor inhibition with verekitug,' said Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development of Upstream Bio. 'We look forward to further assessing the potential translation of this unique mechanism into clinical benefit in patients with severe respiratory diseases, first with top-line Phase 2 clinical data in CRSwNP in the third quarter of this year followed by data in severe asthma in the first half of 2026.' Data presented used an in silico system pharmacology modeling approach to provide a mechanism-based understanding for the observed potency of verekitug and are summarized as follows: A digital version of the presentation can be found on the Upstream Bio website. About TSLP and TSLPR Blockade Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy. TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor (TSLPR) presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. About Verekitug Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. Verekitug is currently being evaluated in two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials, the VALIANT trial in patients with severe asthma (NCT06196879) and the VIBRANT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT06164704). Upstream Bio is also initiating a Phase 2 clinical trial (NCT06981078) of verekitug in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In preclinical studies, verekitug demonstrated high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from both CD4+ T cells and ILC2 cells and completely suppressed skin allergic reactions in a non-human primate model, suggesting that it may be effective against multiple types of inflammation. Three clinical trials have been completed for verekitug, including a Phase 1 single-ascending dose (SAD) clinical trial and a Phase 1b multiple-ascending dose (MAD) clinical trial. In these trials, verekitug was well tolerated, had no clinically meaningful immunogenicity, and showed a predictable and consistent pharmacokinetic profile and high subcutaneous bioavailability. About Upstream Bio Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and is initiating development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'continue,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'predict,' 'project,' 'seeks,' 'should,' 'target,' 'will' and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the clinical development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the initiation, timing, progress and results of ongoing and planned clinical trials; expectations for future discussions with regulatory authorities and the potential of the endpoints of the Company's clinical trials to produce data that could support submissions for product approval; expectations regarding the differentiation, safety, efficacy or tolerability of verekitug; expectations regarding the translation of pharmacology modeling data of verekitug to clinical effects; and assessments comparing non-head-to-head clinical data of verekitug to published data for tezepelumab. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio's ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream Bio's ability to fund its development activities and achieve development goals; Upstream Bio's dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio's ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio's financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream Bio's competitors and industry; and other risks and uncertainties described in greater detail under the caption 'Risk Factors' in Upstream Bio's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio's views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Investor and Media Contact: Meggan Buckwell Director, Corporate Communications and Investor Relations [email protected]
